Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.73 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400228 | 0.92 | MTNR1A (0.68) | MTNR1AMTNR1BCHRM2MEN1ALDH1A1 | |
| SCHEMBL8928104 | 0.85 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL660541 | 0.84 | MMP13 (0.70) | MTNR1AMTNR1BMEN1ALDH1A1KMT2A | |
| SCHEMBL8928132 | 0.83 | MTNR1A (0.92) | MTNR1AMTNR1BKMT2AHDAC1 | |
| Hydrochloric Acid SCHEMBL29194804 | 0.83 | MMP13 (0.68) | MTNR1AMTNR1BMEN1ALDH1A1KMT2A | |
| SCHEMBL13391003 | 0.81 | CHRM2 (0.77) | CHRM2MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL18767114 | 0.81 | CHRM2 (0.77) | CHRM2MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL876345 | 0.81 | MTNR1A (0.83) | MTNR1AMTNR1BCHRM2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6127176 | 0.81 | CHRM2 (0.94) | CHRM2MEN1ALDH1A1KMT2AKDM4E | |
| SCHEMBL4916089 | 0.81 | CHRM2 (0.81) | CHRM2MEN1ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221932-A1 | Methods and Uses of Melatonin Ligands | DOMINGUEZ LOPEZ SERGIO (US) | 2016-08-04 | — | — | US | claimed |
| EP-1973868-B1 | Novel elatonin ligands having antidepressant activity as well as sleep inducing properties | UNIV MCGILL (CA) | 2015-09-09 | — | — | EP | claimed |
| WO-2015021535-A1 | METHODS AND USES OF MELATONIN LIGANDS | GOBBI GABRIELLA (CA) | 2015-02-19 | — | — | WO | claimed |
| US-20150045442-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | GOBBI GABRIELLA (CA) | 2015-02-12 | — | — | US | claimed |
| US-20100267836-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | UNIVERSITA DEGLI STUDI DI MILANO (IT) | 2010-10-21 | — | — | US | claimed |
| US-20160221932-A1 | Methods and Uses of Melatonin Ligands | DOMINGUEZ LOPEZ SERGIO (US) | 2016-08-04 | — | — | US | disclosed |
| EP-1973868-B1 | Novel elatonin ligands having antidepressant activity as well as sleep inducing properties | UNIV MCGILL (CA) | 2015-09-09 | — | — | EP | disclosed |
| WO-2015021535-A1 | METHODS AND USES OF MELATONIN LIGANDS | GOBBI GABRIELLA (CA) | 2015-02-19 | — | — | WO | disclosed |
| US-20150045442-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | GOBBI GABRIELLA (CA) | 2015-02-12 | — | — | US | disclosed |
| US-8791163-B2 | Melatonin ligands having antidepressant activity as well as sleep inducing properties | MCGILL UNIVERSITY (CA) | 2014-07-29 | — | — | US | disclosed |
| US-20100267836-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | UNIVERSITA DEGLI STUDI DI MILANO (IT) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221932-A1 | Methods and Uses of Melatonin Ligands | MTNR1A, MTNR1B, MC3R | MTNR1A 1/4885MTNR1B 2/4885CHRM2 63/4885 |
| US-20100267836-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | HCRTR1, HCRTR2, MTNR1A | MTNR1A 3/4885MTNR1B 5/4885CHRM2 58/4885 |
| US-20150045442-A1 | NOVEL MELATONIN LIGANDS HAVING ANTIDEPRESSANT ACTIVITY AS WELL AS SLEEP INDUCING PROPERTIES | HCRTR1, HCRTR2, MTNR1A | MTNR1A 3/4885MTNR1B 5/4885CHRM2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.